These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24549371)

  • 1. Clinical and preclinical characterization of the histamine H(4) receptor antagonist JNJ-39758979.
    Thurmond RL; Chen B; Dunford PJ; Greenspan AJ; Karlsson L; La D; Ward P; Xu XL
    J Pharmacol Exp Ther; 2014 May; 349(2):176-84. PubMed ID: 24549371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects.
    Kollmeier A; Francke K; Chen B; Dunford PJ; Greenspan AJ; Xia Y; Xu XL; Zhou B; Thurmond RL
    J Pharmacol Exp Ther; 2014 Jul; 350(1):181-7. PubMed ID: 24817035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation.
    Ling P; Ngo K; Nguyen S; Thurmond RL; Edwards JP; Karlsson L; Fung-Leung WP
    Br J Pharmacol; 2004 May; 142(1):161-71. PubMed ID: 15131002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INCB38579, a novel and potent histamine H₄ receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions.
    Shin N; Covington M; Bian D; Zhuo J; Bowman K; Li Y; Soloviev M; Qian DQ; Feldman P; Leffet L; He X; He Wang K; Krug K; Bell D; Czerniak P; Hu Z; Zhao H; Zhang J; Yeleswaram S; Yao W; Newton R; Scherle P
    Eur J Pharmacol; 2012 Jan; 675(1-3):47-56. PubMed ID: 22155710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties.
    Strakhova MI; Cuff CA; Manelli AM; Carr TL; Witte DG; Baranowski JL; Vortherms TA; Miller TR; Rundell L; McPherson MJ; Adair RM; Brito AA; Bettencourt BM; Yao BB; Wetter JM; Marsh KC; Liu H; Cowart MD; Brioni JD; Esbenshade TA
    Br J Pharmacol; 2009 May; 157(1):44-54. PubMed ID: 19413570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist.
    Maher MP; Bhattacharya A; Ao H; Swanson N; Wu NT; Freedman J; Kansagara M; Scott B; Li DH; Eckert WA; Liu Y; Sepassi K; Rizzolio M; Fitzgerald A; Liu J; Branstetter BJ; Rech JC; Lebsack AD; Breitenbucher JG; Wickenden AD; Chaplan SR
    Eur J Pharmacol; 2011 Aug; 663(1-3):40-50. PubMed ID: 21575625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Development of Histamine H
    Thurmond RL; Venable J; Savall B; La D; Snook S; Dunford PJ; Edwards JP
    Handb Exp Pharmacol; 2017; 241():301-320. PubMed ID: 28233185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual H3/4R antagonist thioperamide does not fully mimic the effects of the 'standard' H4R antagonist JNJ 7777120 in experimental murine asthma.
    Neumann D; Beermann S; Burhenne H; Glage S; Hartwig C; Seifert R
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):983-90. PubMed ID: 23820873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties.
    Thurmond RL; Desai PJ; Dunford PJ; Fung-Leung WP; Hofstra CL; Jiang W; Nguyen S; Riley JP; Sun S; Williams KN; Edwards JP; Karlsson L
    J Pharmacol Exp Ther; 2004 Apr; 309(1):404-13. PubMed ID: 14722321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis.
    Murata Y; Song M; Kikuchi H; Hisamichi K; Xu XL; Greenspan A; Kato M; Chiou CF; Kato T; Guzzo C; Thurmond RL; Ohtsuki M; Furue M
    J Dermatol; 2015 Feb; 42(2):129-39. PubMed ID: 25491792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H₄ receptor antagonists.
    Savall BM; Chavez F; Tays K; Dunford PJ; Cowden JM; Hack MD; Wolin RL; Thurmond RL; Edwards JP
    J Med Chem; 2014 Mar; 57(6):2429-39. PubMed ID: 24495018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
    Xue X; De Leon-Tabaldo A; Luna-Roman R; Castro G; Albers M; Schoetens F; DePrimo S; Devineni D; Wilde T; Goldberg S; Kinzel O; Hoffmann T; Fourie AM; Thurmond RL
    Sci Rep; 2021 May; 11(1):11066. PubMed ID: 34040108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.
    Bettica P; Nucci G; Pyke C; Squassante L; Zamuner S; Ratti E; Gomeni R; Alexander R
    J Psychopharmacol; 2012 Aug; 26(8):1058-70. PubMed ID: 21730017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor.
    Deml KF; Beermann S; Neumann D; Strasser A; Seifert R
    Mol Pharmacol; 2009 Nov; 76(5):1019-30. PubMed ID: 19720730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of the histamine H4 receptor reduces LPS-induced TNF production in vivo.
    Cowden JM; Yu F; Challapalli M; Huang JF; Kim S; Fung-Leung WP; Ma JY; Riley JP; Zhang M; Dunford PJ; Thurmond RL
    Inflamm Res; 2013 Jun; 62(6):599-607. PubMed ID: 23532396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.
    Katz LB; Gambale JJ; Rothenberg PL; Vanapalli SR; Vaccaro N; Xi L; Sarich TC; Stein PP
    Diabetes Obes Metab; 2012 Aug; 14(8):709-16. PubMed ID: 22340428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
    van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
    J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic effect of histamine H4 receptor modulation in the central nervous system.
    Galeotti N; Sanna MD; Ghelardini C
    Neuropharmacology; 2013 Aug; 71():141-7. PubMed ID: 23583928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.